you are here: HomeNewsS ramesh
s ramesh
Jump to
25 Results Found
  • PK Das to take over as Chairman of CBIC from January 1, 2019 Dec 18, 2018 01:23 PM IST

    PK Das to take over as Chairman of CBIC from January 1, 2019

    PK Das will take over from current Chairman S Ramesh, who retires on December 31.

  • Big Deal: Deal street's outlook for 2017 Feb 27, 2017 03:42 PM IST

    Big Deal: Deal street's outlook for 2017

    Watch S Ramesh, MD & CEO at Kotak Investment Banking and Sourav Mallik, Joint MD at Kotak Investment Banking speaking with Nisha Poddar of CNBC-TV18 about deal street's outlook for 2017.

  • Listing of renewable cos to get a good response: S Ramesh Feb 14, 2017 01:27 PM IST

    Listing of renewable cos to get a good response: S Ramesh

    Speaking to CNBC-TV18, Ramesh said that a few top companies from the renewables space are likely to get listed and will receive a good response from the market.

  • Can grow at 18%; expect margins at 30% going ahead: Lupin Aug 10, 2016 11:40 AM IST

    Can grow at 18%; expect margins at 30% going ahead: Lupin

    "If the gross domestic product (GDP) is around 7-8 percent for the country and pharma sector grows at 10-12 percent, Lupin can grow at 18 percent going ahead on the back of its strong strategies," says S Ramesh, CFO of the company.

  • FY17 to be 'watershed' year of double-digit earnings: Envision Jul 22, 2016 09:32 AM IST

    FY17 to be 'watershed' year of double-digit earnings: Envision

    In an interview with CNBC-TV18, Nilesh Shah along with S Ramesh of Kotak Investment Banking shared their views on factors that are supporting market momentum and what is to be expected going forward.

  • Market volatility may delay new IPO launches: S Ramesh Feb 23, 2016 01:22 PM IST

    Market volatility may delay new IPO launches: S Ramesh

    The current market volatility and headwinds in secondary market may delay the pace of IPO launches, S Ramesh, MD and CEO of Kotak Investment Banking.

  • IPO pipeline looks good, divestment to go on in FY16: Kotak Feb 10, 2015 04:00 PM IST

    IPO pipeline looks good, divestment to go on in FY16: Kotak

    There is cause for optimism as we look at fiscal 2016. Experts say number of issuances are slated to hit the market in FY16

  • Lupin scouts for acquisitions in US Oct 21, 2014 04:12 PM IST

    Lupin scouts for acquisitions in US

    Terming the US as a high growth market for the company, the Mumbai-based firm said it aims to grow at around 25 percent in the world's largest drug market.

  • Indian business to do well in Q4FY14: Lupin Feb 21, 2014 10:32 AM IST

    Indian business to do well in Q4FY14: Lupin

    Trizivir and Zymaxid generics' contribution will remain high going ahead, S Ramesh, CFO, Lupin said.

  • Surprise mkt on divestments; supply not an issue: Expert Oct 04, 2013 11:59 AM IST

    Surprise mkt on divestments; supply not an issue: Expert

    Prithvi Haldea, managing director, Prime Database says there are no supply related issues as the pipeline for public service undertakings (PSUs) for divestment is very strong. The problem, Haldea adds, is to do with the government‘s view on the fundamentals of the company and it‘s pricing in the market.

  • See FY14 growth at 15-20%; eye 100 launches in 3 yrs: Lupin Jul 05, 2013 12:13 PM IST

    See FY14 growth at 15-20%; eye 100 launches in 3 yrs: Lupin

    Lupin's S Ramesh expects 15-20 percent growth for FY14 on year-on-year basis. Going ahead, he believes the overall momentum would continue and the company will find growth.

  • Contraceptives basket can fetch $150m from US sales: Lupin Apr 16, 2013 04:34 PM IST

    Contraceptives basket can fetch $150m from US sales: Lupin

    Pharma major Lupin expects sales in the US to touch at least USD 150 million per quarter going ahead, S Ramesh, CFO, said on Tuesday.

  • Novartis verdict a boost; India too big to ignore: Lupin Apr 02, 2013 05:28 PM IST

    Novartis verdict a boost; India too big to ignore: Lupin

    S Ramesh, CFO, Lupin says that the Novartis judgment will not impact market much and it is a positive for domestic pharmaceutical sector. In an interview to CNBC-TV18, he adds, "No company can think of ignoring the Indian market and I do not see MNCs going slow on investment in India."

  • Budget to focus on policy moves; investors buoyant: Kotak Feb 18, 2013 03:57 PM IST

    Budget to focus on policy moves; investors buoyant: Kotak

    S Ramesh, Joint MD, Kotak Investment Banking believes the upcoming Budget would be focusing more on directional moves at the fiscal side. According to him, these moves would ensure continuous foreign flows to the capital markets

  • See over 30% growth in next couple of quarters: Lupin Dec 20, 2012 11:35 AM IST

    See over 30% growth in next couple of quarters: Lupin

    Lupin had a good year in the stock market. In an interview to CNBC-TV18, S Ramesh, president - finance & planning of Lupin says in the first two quarters of the current year, the company has exhibited more than 30 percent growth. "We are fairly confident that we will be able to sustain this in the next couple of quarters," he asserts.

  • No rivals for Suprax; Lupin eyes 22-25% domestic growth Aug 22, 2012 11:11 AM IST

    No rivals for Suprax; Lupin eyes 22-25% domestic growth

    Pharmaceutical company Lupin has become the latest entrant to the Nifty and will be indexed from September 28. The stock has been an outperformer over the months and S Ramesh, CFO of Lupin expects the company's domestic growth to be maintained at 22-25%.

  • 'SEBI move to structurally alter nature of MF industry' Aug 17, 2012 11:55 AM IST

    'SEBI move to structurally alter nature of MF industry'

    The market regulator granted asset management companies (AMCs) flexibility on fees by allowing them to charge up to 30 basis points more as total expense ratio (TER) across schemes from inflows from smaller towns beyond the top 15 cities. S Ramesh, Joint MD of Kotak Investment Banking and Puneet Chaddha CEO of HSBC AMC welcome this move.

  • Lupin sees 20-25% growth in US business in FY13 Mar 29, 2012 11:53 AM IST

    Lupin sees 20-25% growth in US business in FY13

    Pharma major Lupin expects its US business will grow 20-25% in fiscal 2012-13 (April-March), helped by a strong pipeline of generic drugs.

  • 3 New Ways of Selling Down! Jan 07, 2012 02:53 PM IST

    3 New Ways of Selling Down!

    The New Year has brought 3 new mechanisms- 2 that help companies and their promoters to meet the minimum 25% public shareholding limit and the third helps the majority shareholder have more shares accepted in a buyback.

  • Lupin hopeful of getting Fortamet case through Dec 08, 2011 05:31 PM IST

    Lupin hopeful of getting Fortamet case through

    Lupin had launched Fortamet, a diabetic drug, at risk in the US, causing an injunction against the drug. Chief Financial Officer S Ramesh clarified that Fortamet generic was launched only for few days.

  • Lupin aims to grow 25% in FY12, to roll out 100 products Jul 11, 2011 11:50 AM IST

    Lupin aims to grow 25% in FY12, to roll out 100 products

    Lupin, which has been a hot favourite among market experts, is growing ambitious. The drug company is eyeing to launch around 100 more products in the next two to three years.

  • Why are foreign issuers headed to Hong Kong? Jul 02, 2011 11:55 AM IST

    Why are foreign issuers headed to Hong Kong?

    It's the world's biggest bourse by market value and the biggest IPO market for the past 2 years. And Chinese companies aside,

  • Lupin sees more development on NeuClone deal in 5-6 qtrs Jun 01, 2011 05:50 PM IST

    Lupin sees more development on NeuClone deal in 5-6 qtrs

    S Ramesh, CFO of Lupin, in an interview with CNBC-TV18’s Latha Venkatesh and Gautam Broker, said that this agreement might bear fruit in five-six quarters. He also stated that Lupin wants a positive development in this particular area.

  • Why invest in an IPO: Experts explain May 23, 2011 04:44 PM IST

    Why invest in an IPO: Experts explain

    CNBC-TV18's special show Informed Investor, talks in more detail about the primary markets space and how to approach the potential IPOs. It discusses which one is worth a subscription and which one looks like a skip.

  • Govt should focus on sustenance of EOUs: Lupin Feb 22, 2011 03:19 PM IST

    Govt should focus on sustenance of EOUs: Lupin

    Drug firm Lupin is optimistic about performing well in the next fiscal says S Ramesh, chief financial officer of the company. The company aims to maintain 20% growth rate in the next year as well.

Sections